Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

被引：0
|
作者：
Behl, Deepti
Rothe, Michael
Mangat, Pam K.
Garrett-Mayer, Elizabeth
Farrington, Laura Catherine
Crysler, Oxana V.
Dib, Elie G.
Duvivier, Herbert Leon
Hall, Michael J.
Salmon, John Stuart
Alese, Olatunji B.
Marr, Alissa S.
Ngirailemesang, Isa
Polavaram, Latha
Thota, Ramya
Yang, Eddy Shih-Hsin
O'Lone, Raegan
Grantham, Gina N.
Halabi, Susan
Schilsky, Richard L.
机构：
[1] Sutter Sacramento Med Ctr, Sacramento, CA USA
[2] Amer Soc Clin Oncol, Alexandria, VA USA
[3] Canc Treatment Ctr Amer Chicago, Zion, IL USA
[4] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI USA
[5] Michigan Canc Res Consortium, Ypsilanti, MI USA
[6] Canc Treatment Ctr Amer Atlanta, Newnan, GA USA
[7] Fox Chase Canc Ctr, Philadelphia, PA USA
[8] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[9] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[10] Univ Nebraska Med Ctr, Omaha, NE USA
[11] Providence Canc Inst, Portland, OR USA
[12] Canc Res Consortium West Michigan, Grand Rapids, MI USA
[13] Intermt Healthcare, Murray, UT USA
[14] Univ Alabama Birmingham, Sch Med, Dept Radiat Oncol, ONeal Comprehens Canc Ctr, Birmingham, AL USA
[15] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
122
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [1] Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study
    Ahn, E.
    Rothe, M.
    Mangat, P. K.
    Garrett-Mayer, E.
    Al Baghdadi, T.
    Baron, A. D.
    Krauss, J. C.
    Balmanoukian, A. S.
    Bauman, J. R.
    Hameed, M. K.
    Mileham, K. F.
    Thota, R.
    Gold, P. J.
    Meric-Bernstam, F.
    Powell, S. F.
    Yang, E. S.
    O'Lone, R.
    Grantham, G. N.
    Halabi, S.
    Schilsky, R. L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S583 - S584
  • [2] Talazoparib (Tala) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
    Yost, Kathleen J.
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Duvivier, Herbert Leon
    Ahn, Eugene R.
    Chiu, Vi Kien
    Khalil, Maged F.
    Kim, Brian
    Prinz, Allison Marie
    Grantham, Gina N.
    Gregory, Abby
    Hinshaw, Dominique C.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 106 - 106
  • [3] Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
    Grem, Jean L.
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Khalil, Maged F.
    Rogosin, Shane O.
    Salmon, John Stuart
    Cannon, Timothy Lewis
    Grantham, Gina N.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [4] Temsirolimus (T) in patients (pts) with solid tumors with PTEN mutation (mut): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Wentzel, Kristopher
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Ding, Li
    Pisick, Evan
    Krishnan, Mridula
    Behl, Deepti
    Alese, Olatunji B.
    Calfa, Carmen J.
    Cooper, Kathrine A.
    Duvivier, Herbert L.
    Induru, Raghava Reddy
    Ruzich, Janet C.
    Zhao, Song
    Grantham, Gina N.
    Gregory, Abigail
    Halabi, Susan
    Schilsky, Richard L.
    CANCER RESEARCH, 2023, 83 (08)
  • [5] Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
    Ahn, Eugene R.
    Garrett-Mayer, Elizabeth
    Halabi, Susan
    Mangat, Pam K.
    Calfa, Carmen Julia
    Alva, Ajjai Shivaram
    Suhag, Vijay S.
    Hamid, Omid
    Dotan, Efrat
    Yang, Eddy Shih-Hsin
    Alese, Olatunji B.
    Yost, Kathleen J.
    Marr, Alissa S.
    Palmer, Martin Clive
    Thompson, Forrest L.
    Rygiel, Andrew Lawrence
    Anderson, Sarah T.
    Islam, Samiha
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
    Pisick, Evan P.
    Garrett-Mayer, Elizabeth
    Halabi, Susan
    Mangat, Pam K.
    Yang, Eddy Shih-Hsin
    Dib, Elie G.
    Burgess, Earle Frederick
    Zakem, Michael Howard
    Rohatgi, Nitin
    Bilen, Mehmet Asim
    Warren, Sasha L.
    Anderson, Sarah T.
    Rygiel, Andrew Lawrence
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Talazoparib (Tala) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
    Srkalovic, Gordan
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Ahn, Eugene R.
    Brouse, Gregory
    Chan, John K.
    Mehmi, Inderjit
    Khalil, Maya
    Duvivier, Herbert Leon
    Gaba, Anu G.
    Leuva, Harshraj
    Thota, Ramya
    Yost, Kathleen J.
    Grantham, Gina N.
    Gregory, Abigail
    Hinshaw, Dominique C.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
    Calfa, Carmen Julia
    Rothe, Michael
    Srkalovic, Gordan
    Duvivier, Herbert Leon
    Behl, Deepti
    Straughn, J. Michael
    Yost, Kathleen J.
    Mehmi, Inderjit
    Pisick, Evan P.
    Sharma, Bhavina B.
    Thota, Ramya
    Veljovich, Dan Steven
    Alese, Olatunji B.
    Cannon, Timothy Lewis
    Gaba, Anu G.
    Urba, Walter John
    von Mehren, Margaret
    Grantham, Gina N.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Srkalovic, Gordan
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Nazemzadeh, Reza
    Cannon, Timothy Lewis
    Duvivier, Herbert Leon
    Yost, Kathleen J.
    Pakkala, Suchita
    Alva, Ajjai Shivaram
    Behl, Deepti
    Gold, Philip Jordan
    Calfa, Carmen Julia
    Ngirailemesang, Melissa
    Powell, Steven Francis
    O'Lone, Raegan
    Grantham, Gina N.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Abemaciclib in patients (pts) with esophageal cancer (EC) with CDKN2A loss or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
    Al Baghdadi, Tareq
    Rothe, Michael
    Mangat, Pam K.
    Garrett-Mayer, Elizabeth
    Yost, Kathleen J.
    Chiu, Vi Kien
    Duvivier, Herbert Leon
    Mckean, Meredith
    Rueter, Jens
    Taylor, Mark A.
    Grantham, Gina N.
    Gregory, Abby
    Hinshaw, Dominique C.
    Halabi, Susan
    Schilsky, Richard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 308 - 308
12345